Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Driscoll

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 2015
β-Glucan-Activated Human B Lymphocytes Participate in Innate Immune Responses by Releasing Proinflammatory Cytokines and Stimulating Neutrophil ChemotaxisMohamed F Ali, Christopher B Driscoll, Paula R Walters, et al.
Stem Cell Research & Therapy|April 19, 2015
Nuclear reprogramming with a non-integrating human RNA virusChristopher B Driscoll, Jason M Tonne, Moustafa El Khatib, et al.
Molecular Therapy. Methods & Clinical Development|January 3, 2022
miRNA-mediated control of exogenous <i>OCT4</i> during mesenchymal-epithelial transition increases measles vector reprogramming efficiencyRamya Rallabandi, Brenna Sharp, Conrad Cruz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 27, 2017
Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment EfficacyKevin G Shim, Shane Zaidi, Jill Thompson, et al.
Journal for Immunotherapy of Cancer|July 19, 2019
Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicityMatthew R Schuelke, Phonphimon Wongthida, Jill Thompson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 3, 2020
Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell ResponsesAmanda L Huff, Laura Evgin, Jill Thompson, et al.
Neuro-Oncology|May 28, 2020
Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumorsPhonphimon Wongthida, Matthew R Schuelke, Christopher B Driscoll, et al.
Molecular Therapy Oncolytics|October 9, 2018
APOBEC3 Mediates Resistance to Oncolytic Viral TherapyAmanda L Huff, Phonphimon Wongthida, Timothy Kottke, et al.
Nature Communications|June 26, 2020
Oncolytic virus-derived type I interferon restricts CAR T cell therapyLaura Evgin, Amanda L Huff, Phonphimon Wongthida, et al.
Cancer Immunology Research|April 4, 2019
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line TreatmentLaura Evgin, Amanda L Huff, Timothy Kottke, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 2015
β-Glucan-Activated Human B Lymphocytes Participate in Innate Immune Responses by Releasing Proinflammatory Cytokines and Stimulating Neutrophil ChemotaxisMohamed F Ali, Christopher B Driscoll, Paula R Walters, et al.
Stem Cell Research & Therapy|April 19, 2015
Nuclear reprogramming with a non-integrating human RNA virusChristopher B Driscoll, Jason M Tonne, Moustafa El Khatib, et al.
Molecular Therapy. Methods & Clinical Development|January 3, 2022
miRNA-mediated control of exogenous <i>OCT4</i> during mesenchymal-epithelial transition increases measles vector reprogramming efficiencyRamya Rallabandi, Brenna Sharp, Conrad Cruz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 27, 2017
Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment EfficacyKevin G Shim, Shane Zaidi, Jill Thompson, et al.
Journal for Immunotherapy of Cancer|July 19, 2019
Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicityMatthew R Schuelke, Phonphimon Wongthida, Jill Thompson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 3, 2020
Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell ResponsesAmanda L Huff, Laura Evgin, Jill Thompson, et al.
Neuro-Oncology|May 28, 2020
Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumorsPhonphimon Wongthida, Matthew R Schuelke, Christopher B Driscoll, et al.
Molecular Therapy Oncolytics|October 9, 2018
APOBEC3 Mediates Resistance to Oncolytic Viral TherapyAmanda L Huff, Phonphimon Wongthida, Timothy Kottke, et al.
Nature Communications|June 26, 2020
Oncolytic virus-derived type I interferon restricts CAR T cell therapyLaura Evgin, Amanda L Huff, Phonphimon Wongthida, et al.
Cancer Immunology Research|April 4, 2019
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line TreatmentLaura Evgin, Amanda L Huff, Timothy Kottke, et al.
Pageof 2